NCT03843775View on ClinicalTrials.gov

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

September 2, 2023

Study Completion Date

September 2, 2023

Conditions
Advanced BRAF Mutant Cancers
Interventions
DRUG

Binimetinib

Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID

DRUG

Encorafenib

encorafenib 450 mg oral QD

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity), Commack

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

Sponsors

Collaborators (1)

Array BioPharma
All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER